CCR5Δ32 Deletion as a Protective Factor in Czech First-Wave COVID-19 Subjects

Infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease (COVID-19), has spread widely around the globe. Significant inter-individual differences have been observed during the course of the infection, which suggests that genetic susceptibil...

Full description

Saved in:
Bibliographic Details
Published in:Physiological research 2021-02, Vol.70 (1), p.111-115
Main Authors: HUBACEK, J, DUSEK, L, MAJEK, O, ADAMEK, V, CERVINKOVA, T, DLOUHA, D, PAVEL, J, ADAMKOVA, V
Format: Article
Language:English
Subjects:
Acquired immune deficiency syndrome
AIDS
Asymptomatic
CCR5 protein
Chemokine receptors
Chemokines
Coronaviridae
Coronaviruses
COVID-19
Diabetes
Disease transmission
Ethnicity
Gene deletion
HIV
Human immunodeficiency virus
Infections
Mortality
Mutation
Pathogenesis
Polymorphism
Population
Rapid Communication
Severe acute respiratory syndrome coronavirus 2
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease (COVID-19), has spread widely around the globe. Significant inter-individual differences have been observed during the course of the infection, which suggests that genetic susceptibility may be a contributing factor. CC chemokine receptor 5 (CCR5), which acts as a co-receptor for the entry of HIV-1 into cells, is promising candidate whose can have an influence on SARS-CoV-2 infection. A genetic mutation known as CCR5Δ32, consisting of a 32-nucleotide deletion, encodes a truncated protein that protects homozygous carriers of the deletion from HIV-1 infection. Similarly, inhibition of CCR5 seems to be protective against COVID-19. In our study, we successfully genotyped 416 first-wave SARS-CoV-2-positive infection survivors (164 asymptomatic and 252 symptomatic) for CCR5Δ32, comparing them with a population based sample of 2,404 subjects. We found the highest number (P=0.03) of CCR5Δ32 carriers in SARS-CoV-2-positive/COVID-19-asympto-matic subjects (23.8 %) and the lowest number in SARS-CoV-2-positive/COVID-19-symptomatic patients (16.7 %), with frequency in the control population in the middle (21.0 %). We conclude that the CCR5Δ32 I/D polymorphism may have the potential to predict the severity of SARS-CoV-2 infection.
ISSN:0862-8408
1802-9973
DOI:10.33549/physiolres.934647